Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate-risk karyotype in first complete remission.

about

Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate-risk karyotype in first complete remission.

Item

http://www.wikidata.org/entity/Q52873870

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Impact of early remission by i ...... e in first complete remission.

@en

Impact of early remission by i ...... e in first complete remission.

@nl

type

Item

label

Impact of early remission by i ...... e in first complete remission.

@en

Impact of early remission by i ...... e in first complete remission.

@nl

prefLabel

Impact of early remission by i ...... e in first complete remission.

@en

Impact of early remission by i ...... e in first complete remission.

@nl

P1476

Impact of early remission by i ...... e in first complete remission.

@en

P2093

Bernd Dörken

http://www.w3.org/2001/XMLSchema#string

Christian F Jehn

http://www.w3.org/2001/XMLSchema#string

Il-Kang Na

http://www.w3.org/2001/XMLSchema#string

Lam G Vuong

http://www.w3.org/2001/XMLSchema#string

Philipp G Hemmati

http://www.w3.org/2001/XMLSchema#string

Philipp le Coutre

http://www.w3.org/2001/XMLSchema#string

Renate Arnold

http://www.w3.org/2001/XMLSchema#string

Theis H Terwey

http://www.w3.org/2001/XMLSchema#string

P2860

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.

Acute myeloid leukaemia in adults.

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.

Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group.

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.

P304

431-438

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/EJH.12449

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25220715

http://www.w3.org/2001/XMLSchema#string

P921

karyotype